Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Technology to Be Used in Groundbreaking Studies of
Neurological Disease
GeneChip(R) Microarray Technology Enabling Perlegen Sciences to Study
Alzheimer's Disease, Autism and Parkinson's Disease
SANTA CLARA, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Affymetrix
(NASDAQ:AFFX) GeneChip technology is now enabling three unprecedented studies
of complex brain disease. Perlegen Sciences recently announced that they are
using high density Affymetrix GeneChip microarrays for landmark studies of the
genetic causes of Alzheimer's disease, autism, and Parkinson's disease.
Understanding the genetics of complex disease requires huge amounts of
information. Neurological diseases can be particularly challenging due to the
difficulty in classifying phenotypes. Affymetrix photolithographic microarray
technology provides the most genetic information, enabling scientists for the
first time to cost-effectively analyze whole genomes with sufficient resolution
to identify the genetic variations that could play a role in these diseases.
Perlegen, which was formed in late 2000 as a spin-off from Affymetrix, is using
Affymetrix microarrays to produce up to 20 million genotypes per day. Perlegen
has developed the world's leading infrastructure for high throughput genotyping
by combining this technology with its proprietary genetics, systems, and
informatics expertise. Using Affymetrix technology, Perlegen routinely
analyzes over 200,000 SNPs in individual samples and up to 1.5 million SNPs in
pooled samples.
Combining this high throughput platform with well-characterized DNA samples and
scientific expertise from leading research institutions, such as the Mayo
Clinic, offers a huge opportunity for progress in these significant human
diseases. Funding for these important projects is provided by diverse public
and private groups such as NIMH, NIA, Michael J. Fox Foundation, and AGRE.
"We congratulate Perlegen on these studies," said Greg Yap, Affymetrix' Vice
President, DNA Products. "We are enthusiastic that they continue to pioneer
the advanced use of GeneChip microarray technology for high resolution whole
genome SNP scans and genome-wide association studies. Perlegen is blazing a
trail for others to build upon. Affymetrix' goal is to make whole genome
analysis accessible to everyone."
Perlegen Genotyping Services Available Through Affymetrix
Access to Perlegen's high-throughput genotyping facility is now available
through Affymetrix on a simple, fee-for-service basis. These services --
covering projects ranging from a few thousand to 50,000 SNPs, and up to
thousands of samples -- are designed to conveniently meet the needs of
researchers eager to identify genetic loci associated with inherited diseases.
SNPs to be genotyped can be selected by customers from Perlegen's portfolio of
over 1.5 million previously validated SNP assays, as well as from public
sources. Affymetrix' global sales infrastructure provides before and
after-sales support.
Broad Portfolio of Affymetrix Genotyping Products
Affymetrix is also translating its ongoing innovations in GeneChip technology
into market-leading products for DNA analysis that can be used by scientists in
their own labs. The GeneChip Mapping 100K Array Set is the first product for
genotyping over 100,000 SNPs, enabling researchers for the first time to study
the genes associated with complex disease and drug response in their own labs.
The 100K is first in a family of products for genome-wide association studies
and is being used by more than 30 customers today. Affymetrix' 10K and 100K
SNP products feature a proven assay that has been used in more than 20
peer-reviewed publications to date. Affymetrix has also recently launched
products for genotyping customer-selected SNP panels. MegAllele genotyping
reagents, developed by ParAllele, are available through Affymetrix and offer a
cost-effective solution for customers to genotype selected SNPs.
About Affymetrix:
Affymetrix is a pioneer in creating breakthrough tools that are driving the
genomic revolution. By applying the principles of semiconductor technology to
the life sciences, Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers include
pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products
companies as well as academic, government and other non-profit research
institutes. Affymetrix offers an expanding portfolio of integrated products and
services, including its integrated GeneChip brand platform, to address growing
markets focused on understanding the relationship between genes and human
health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses,
uncertainties relating to technological approaches (including uncertainties
relating to the outcome of the neurological studies discussed in this press
release), manufacturing, product development, market acceptance, personnel
retention, uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory approvals,
competition, risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other risk factors
are discussed in Affymetrix' Form 10-K for the year ended December 31, 2003 and
other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any forward- looking statements
contained herein to reflect any change in Affymetrix' expectations with regard
thereto or any change in events, conditions, or circumstances on which any such
statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks
owned or used by Affymetrix, Inc.
DATASOURCE: Affymetrix
CONTACT: Wes Conard, Associate Director, Public Relations,
+1-408-731-5791, or +1-415-385-4455; or investors, Doug Farrell, Vice
President, Investor Relations, +1-408-731-5285, both of Affymetrix
Web site: http://www.affymetrix.com/